RA0152

antibody from Oursmab

Targeting: CSF1R C-FMS, CD115, CSFR, FMS

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0152

Provider

Oursmab

Product name

Cabiralizumab (Biosimilar Reference Antibody) (CSF1R)

Antibody type

Monoclonal

Description

Cabiralizumab is an investigational humanized monoclonal antibody designed for cancer therapy, specifically functioning as an inhibitor of the colony-stimulating factor 1 receptor (CSF-1R). It was developed with the primary goal of modulating the tumor microenvironment by targeting immunosuppressive tumor-associated macrophages (TAMs). Clinical trials explored its use, particularly in combination with checkpoint inhibitors such as nivolumab (anti-PD-1), for advanced solid tumors including pancreatic cancer, renal cell carcinoma, and non-small cell lung cancer. While early-phase studies demonstrated some potential for synergistic activity, its overall development has been limited, and the drug has not progressed to widespread regulatory approval.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.